Basic HTML Version
Conclusions
The PRO-Kinetic stent with amorphous PROBIO
··
®
coating shows a good performance
with regard to device, procedure and lesion success
The primary endpoint TVF at 6 months was 11.9 %
··
The 6-month MACE rate
··
6
was 9.9 % with clinically driven TLR of 7.4 %
The 12-month MACE rate
··
6
was 11.4 % with clinically driven TLR of 7.9 %
At 12-month FU no stent thrombosis was noted
··
The 6-month Late Lumen Loss of 0.59 mm is very low for a BMS
··
Modern Bare Metal Stent platforms continue to play an important role in PCI,
··
as late stent thrombosis and the use of double anti-platelet therapy are debated
6
MACE defined as only cardiac death, MI, ischemia-driven TLR, TVR-CABG